Antiviral therapy by targeting nanoparticles to CD4+ cells for the delivery of SIV-specific RNA-guided Cas9 nucleases

• L. Giavedoni,
• L. Smith,
• E. Carnes,
• C. Lino,
• V. Hodara,
• K. Reimann,
• L. Parodi

Affiliations

L. Giavedoni

Texas Biomedical Research Institute, San Antonio, TX, USA

L. Smith

University of Texas Health Science Center, San Antonio, TX, USA; Texas Biomedical Research Institute, San Antonio, TX, USA

E. Carnes

University of New Mexico, Albuquerque, NM, USA; Sandia National Laboratories, Albuquerque, NM, USA

C. Lino

Sandia National Laboratories, Albuquerque, NM, USA

V. Hodara

Texas Biomedical Research Institute, San Antonio, TX, USA

K. Reimann

University of Massachusetts Medical School, Boston, MA, USA

L. Parodi

Texas Biomedical Research Institute, San Antonio, TX, USA